325 related articles for article (PubMed ID: 33451059)
1. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
[TBL] [Abstract][Full Text] [Related]
2. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment options for advanced biliary tract carcinoma.
Xie C; McGrath NA; Monge Bonilla C; Fu J
J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
[TBL] [Abstract][Full Text] [Related]
5. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
[TBL] [Abstract][Full Text] [Related]
6. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
Zhu AX; Hezel AF
Hepatology; 2011 Feb; 53(2):695-704. PubMed ID: 21274890
[TBL] [Abstract][Full Text] [Related]
7. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
8. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
9. [Biliary tract cancer: on the way to a personalized therapy].
Sinn M; Wege H; Stein A
Dtsch Med Wochenschr; 2020 Apr; 145(7):442-446. PubMed ID: 32236923
[TBL] [Abstract][Full Text] [Related]
10. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
[TBL] [Abstract][Full Text] [Related]
11. Is there any place for novel agents in treating biliary tract cancer?
Perego G; Burgio V; Nozza R; Longobardo G; Bernecich M; Luciani A; Petrelli F
Med Oncol; 2021 Feb; 38(2):19. PubMed ID: 33543377
[TBL] [Abstract][Full Text] [Related]
12. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
Demols A; Bucalau AM; Mans L
Curr Opin Oncol; 2022 Jul; 34(4):403-411. PubMed ID: 35837710
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
[No Abstract] [Full Text] [Related]
14. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of biliary tract cancers.
Uson Junior PLS; Bogenberger J; Borad MJ
Curr Opin Gastroenterol; 2020 Mar; 36(2):85-89. PubMed ID: 31972599
[TBL] [Abstract][Full Text] [Related]
17. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Kapacee ZA; Knox JJ; Palmer D; Blagden SP; Lamarca A; Valle JW; McNamara MG
Med Oncol; 2020 Jun; 37(7):61. PubMed ID: 32529264
[TBL] [Abstract][Full Text] [Related]
18. Role of chemotherapy in treatments for biliary tract cancer.
Furuse J; Kasuga A; Takasu A; Kitamura H; Nagashima F
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):337-41. PubMed ID: 22456744
[TBL] [Abstract][Full Text] [Related]
19. Review of gemcitabine in biliary tract carcinoma.
Scheithauer W
Semin Oncol; 2002 Dec; 29(6 Suppl 20):40-5. PubMed ID: 12577232
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
Fornaro L; Vivaldi C; Cereda S; Leone F; Aprile G; Lonardi S; Silvestris N; Santini D; Milella M; Caparello C; Musettini G; Pasquini G; Falcone A; Brandi G; Sperduti I; Vasile E;
J Exp Clin Cancer Res; 2015 Dec; 34():156. PubMed ID: 26693938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]